Cigna’s pharmacy benefits unit Evernorth said the deal will bring prices down for employers and their workers.

Cigna said on Wednesday it was launching an add-on to pharmacy benefit management plans in which patients could pay no more ...

The FDA approved dihydroergotamine (DHE) mesylate injection (Brekiya) to treat acute migraine (with or without aura) and cluster headaches in adults, Amneal Pharmaceuticals announced Thursday. The ...

Tirzepatide promoted greater weight loss in individuals with obesity than semaglutide in a clinical trial that compared the ...

Tirzepatide (trade name Zepbound) promoted greater weight loss in individuals with obesity than did semaglutide (trade name Wegovy) in a clinical ...

Hims & Hers rebounds with key partnerships and launches, achieving 111% YoY revenue growth. Learn more about HIMS stock here.

Caremark negotiated an undisclosed lower net price for Wegovy over Zepbound on its standard formularies, offering savings on Novo Nordisk's drug to clients that opt into those plans. Get local ...

Novo Nordisk stock rose after the Danish pharma giant posted better-than-expected quarterly earnings, but cuts its guidance for the year. For the full year, the company now expects sales growth ...

Q1 Wegovy sales rose 85% to DKK 17.36 billion; Ozempic up 18% to DKK 32.72 billion. Novo Nordisk's Q1 sales hit $10.89 billion, missing the $11.64 billion consensus estimate. Don’t miss this ...